Meeting
2017 Genitourinary Cancers Symposium
Effect of NKTR-214 on the number and activity of CD8+ tumor infiltrating lymphocytes in patients with advanced renal cell carcinoma.
Authors
Michael E. Hurwitz
Yale School of Medicine, New Haven, CT
Michael E. Hurwitz , Adi Diab , Chantale Bernatchez , Cara L. Haymaker , Harriet M. Kluger , Michael T. Tetzlaff , Ivan Gergel , Mary Tagliaferri , Michael Imperiale , Sandra Aung , Ute Hoch , Jonathan Zalevsky , Patrick Hwu , Mario Sznol , Nizar M. Tannir
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer
Track
Renal Cell Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
02869295
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 454)
DOI
10.1200/JCO.2017.35.6_suppl.454
Abstract #
454
Poster Bd #
D17
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
![A phase 1b study of tbio-4101 (autologous selected and expanded tumor-infiltrating lymphocytes [TILs]) with pembrolizumab in patients with anti-PD-1–resistant, advanced head and neck squamous cell carcinoma (aHNSCC).](https://d201v5jt9ylckg.cloudfront.net/316/15842/238506/238506_A1293_poster_pv.jpg)
A phase 1b study of tbio-4101 (autologous selected and expanded tumor-infiltrating lymphocytes [TILs]) with pembrolizumab in patients with anti-PD-1–resistant, advanced head and neck squamous cell carcinoma (aHNSCC).
First Author: Kedar Kirtane
Poster
2020 Genitourinary Cancers Symposium
PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC).
First Author: Nizar M. Tannir
Poster
2019 ASCO Annual Meeting
A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma.
First Author: Nizar M. Tannir
Poster
2019 ASCO Annual Meeting
Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.
First Author: Michael E. Hurwitz